drugset / Trial / NCT01812135

Safety and Immunogenicity of EV71 Vaccine With or Without Aluminum Adjuvant in Infants

NCT01812135

Phase 2 Withdrawn Sinovac Biotech Co., Ltd
RandomizedParallel-groupDouble-blindPrevention

Summary

A randomized, double-blind, phase II-02 clinical trial is to evaluate the safety and immunogenicity of an inactivated EV71 vaccine with or without aluminum adjuvant

Timeline

Start
2011-09
Primary completion
2011-11
Completion
2011-12

Drugs

EvaluationDrugModalityDoseRoute
Subject EV71 vaccine Vaccine 400 iu